MARKET

GALT

GALT

Galectin Therapeutics Inc
NASDAQ
1.320
-0.070
-5.04%
After Hours: 1.400 +0.08 +6.06% 19:06 05/13 EDT
OPEN
1.420
PREV CLOSE
1.390
HIGH
1.420
LOW
1.310
VOLUME
113.81K
TURNOVER
--
52 WEEK HIGH
3.280
52 WEEK LOW
0.7260
MARKET CAP
83.40M
P/E (TTM)
-1.7426
1D
5D
1M
3M
1Y
5Y
1D
Largest borrow rate increases among liquid names
TipRanks · 14h ago
Galectin Therapeutics presents NAVIGATE trial results at EASL 2025
TipRanks · 1d ago
Galectin Therapeutics Updates Corporate Presentation on Belapectin
TipRanks · 1d ago
Galectin Therapeutics Issues Presentation Highlighting Its Focused Pipeline, MASH Cirrhosis And Oncology, Developing Galectin-Based Therapeutics To Improve The Lives Of Patients With Chronic Liver Diseases And Cancer
Benzinga · 1d ago
Weekly Report: what happened at GALT last week (0505-0509)?
Weekly Report · 1d ago
Largest borrow rate increases among liquid names
TipRanks · 05/05 12:45
Weekly Report: what happened at GALT last week (0428-0502)?
Weekly Report · 05/05 12:15
Weekly Report: what happened at GALT last week (0421-0425)?
Weekly Report · 04/28 12:28
More
About GALT
More
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Recently
Symbol
Price
%Change

Webull offers Galectin Therapeutics Inc stock information, including NASDAQ: GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.